肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NEJM：局限性前列腺癌接受前列腺根治术可显著延长生存期

2018-12-13 zhangfan MedSci原创

局限性前列腺癌前列腺根治术Gleason评分
关注

研究发现，局限性前列腺癌接受前列腺根治术可显著延长生存期， Gleason评分和囊外扩张是预测患者预后的重要因素

根治性前列腺切除术可降低局限性前列腺癌患者的死亡率，但其长期疗效尚缺乏有效的随访研究。

1989-1999年间，695名观察等待或接受根治性前列腺切除术的局部前列腺癌的男性参与本次研究，随访至2017年。研究的主要终点全因死亡、前列腺癌死亡以及转移。

截止2017年底，347名接受手术的患者中261人死亡，348名观察等待的患者中292人死亡，其中手术组以及观察组死于前列腺的患者数分别为71和110人（RR=0.55）。23年间，手术组患者的寿命平均延长2.9年。在接受手术的人群中，囊外扩张人群的前列腺癌的死亡风险是非囊外扩展人群的5倍，Gleason得分7以上人群的死亡风险是6以下人群的10倍。

研究发现，局限性前列腺癌接受前列腺根治术可显著延长生存期， Gleason评分和囊外扩张是预测患者预后的重要因素。

原始出处：

Anna Bill-Axelson et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.N Engl J Med， December 13， 2018.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2019-11-09 haouestc

    #局限性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 124a5940m50暂无昵称

    Nice

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 仁者大医

    #生存期#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 bluefate122

    #根治术#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 yang0212

    #局限性前列腺癌#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-15 jeanqiuqiu

    #根治#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-14 1ddf0692m34(暂无匿称)

    学习了谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 盖伦

    前列腺癌还是个热点啊

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 一个字-牛

    学习了谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1924034, encodeId=044319240344f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Nov 09 18:40:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355475, encodeId=9fa03554e5bc, content=Nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db792503889, createdName=124a5940m50暂无昵称, createdTime=Sat Dec 15 09:21:39 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378199, encodeId=527c13e819923, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399726, encodeId=02801399e2600, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460470, encodeId=f41614604e0c0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586124, encodeId=ec5f1586124d6, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Dec 15 02:40:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355393, encodeId=b6d5355393ef, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 14 13:10:16 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355308, encodeId=d58a35530869, content=前列腺癌还是个热点啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/24/d9d14db78de202d73276f47d8d8e2596.jpg, createdBy=3b682249905, createdName=盖伦, createdTime=Thu Dec 13 13:49:28 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355306, encodeId=3d42355306b8, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Dec 13 12:45:43 CST 2018, time=2018-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355299, encodeId=107c35529928, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Dec 13 12:05:31 CST 2018, time=2018-12-13, status=1, ipAttribution=)]
    2018-12-13 kafei

    学习学习谢谢

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

JCO：无转移生存率是局限性前列腺癌总生存率的有力替代物

众所周知中危与高危局限性前列腺癌的辅助治疗减少这种疾病的死亡人数。总生存率（OS）的替代指标可以加快新辅助疗法的评价。

NEJM：局限性前列腺癌患者，接受哪种治疗方法更好？

目前，通过前列腺特异性抗原（PSA）检测的前列腺癌治疗效果的比较仍然不确定。研究人员比较了主动监测，前列腺癌根治术，以及外照射放疗用于治疗临床局限性前列腺癌的治疗效果。在1999年至2009年间，共有82429名50至69岁的男性接受了PSA测试; 2664名参与者被诊断为局限性前列腺癌，共有1643名参与者同意接受随机化的主动监测（545人），外科手术（553），或放疗（545）。主要成果是平均

NEJM：转移性前列腺癌DNA-修复基因突变率远高于局部前列腺癌

DNA-修复基因如BRCA2的基因突变与致命性前列腺癌的发病风险增加相关。虽然局部前列腺癌患者的DNA修复基因突变的发生率是不足以保证常规检测，但是转移性前列腺癌患者的这种基因突变的频率尚未确定。 研究共纳入692名转移性前列腺癌患者，分离生殖细胞的DNA，并使用多重测序分析来评估在20个DNA修复基因与常染色体显性遗传性癌症易感综合征相关的突变。 结果，82名男性（11.8%）中共发

Eur Urol：不同的初次治疗方案对局限性前列腺癌患者术后生存质量影响的系统评价。

对于临床局限性前列腺癌，目前循证管理包括主动监测、手术、外放射治疗（EBRT）和近距离放疗。不同的治疗方式对生活质量（QOL）的影响是不确定的。

2018 ASTRO指南：局限性前列腺癌大分割放射治疗（概要）

2018年10月，美国放射治疗及肿瘤学会(ASTRO)发布了局限性前列腺癌大分割放射治疗指南，主要目的是针对适度的大分割（240-340 cGy 每部分）超大分割 (500 cGy 或更多每部分) 放疗治疗局限性前列腺癌提供指导建议。

Eur Uro：中/高风险局限性前列腺癌最终治疗的种族差异：设施特征和社会经济特征的影响。

过去十年来，前列腺癌 (PCa) 生存率在黑人与白人之间的差距扩大了。研究人员推测，这种差异可能部分归因于种族间最终治疗率（放射治疗或外科治疗）的差异。